NASDAQ:OLMA

Olema Pharmaceuticals Competitors

$32.84
+0.12 (+0.37 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$31.81
Now: $32.84
$33.15
50-Day Range
$27.81
MA: $39.93
$53.64
52-Week Range
$26.74
Now: $32.84
$60.27
Volume54,293 shs
Average Volume151,454 shs
Market Capitalization$1.32 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Olema Pharmaceuticals (NASDAQ:OLMA) Vs. SDGR, GLPG, AVIR, SAGE, BHVN, and HCM

Should you be buying OLMA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Olema Pharmaceuticals, including Schrödinger (SDGR), Galapagos (GLPG), Atea Pharmaceuticals (AVIR), Sage Therapeutics (SAGE), Biohaven Pharmaceutical (BHVN), and Hutchison China MediTech (HCM).

Schrödinger (NASDAQ:SDGR) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Insider & Institutional Ownership

41.3% of Schrödinger shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Olema Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Olema Pharmaceuticals00403.00

Schrödinger currently has a consensus target price of $85.50, indicating a potential upside of 15.70%. Olema Pharmaceuticals has a consensus target price of $60.6667, indicating a potential upside of 84.73%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Schrödinger.

Valuation & Earnings

This table compares Schrödinger and Olema Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million60.48$-24,570,000.00N/AN/A
Olema PharmaceuticalsN/AN/AN/AN/AN/A

Olema Pharmaceuticals has lower revenue, but higher earnings than Schrödinger.

Profitability

This table compares Schrödinger and Olema Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Olema PharmaceuticalsN/AN/AN/A

Summary

Olema Pharmaceuticals beats Schrödinger on 6 of the 8 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Valuation & Earnings

This table compares Galapagos and Olema Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion5.08$167.83 million$5.4614.25
Olema PharmaceuticalsN/AN/AN/AN/AN/A

Galapagos has higher revenue and earnings than Olema Pharmaceuticals.

Analyst Ratings

This is a breakdown of current recommendations for Galapagos and Olema Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos211402.12
Olema Pharmaceuticals00403.00

Galapagos currently has a consensus target price of $143.7273, indicating a potential upside of 84.72%. Olema Pharmaceuticals has a consensus target price of $60.6667, indicating a potential upside of 84.73%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Galapagos.

Insider & Institutional Ownership

11.2% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Galapagos and Olema Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos-70.67%-11.78%-5.58%
Olema PharmaceuticalsN/AN/AN/A

Summary

Olema Pharmaceuticals beats Galapagos on 5 of the 8 factors compared between the two stocks.

Olema Pharmaceuticals (NASDAQ:OLMA) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Olema Pharmaceuticals and Atea Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olema PharmaceuticalsN/AN/AN/AN/AN/A
Atea PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for Olema Pharmaceuticals and Atea Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olema Pharmaceuticals00403.00
Atea Pharmaceuticals00403.00

Olema Pharmaceuticals presently has a consensus price target of $60.6667, indicating a potential upside of 84.73%. Atea Pharmaceuticals has a consensus price target of $69.3333, indicating a potential upside of 22.69%. Given Olema Pharmaceuticals' higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Profitability

This table compares Olema Pharmaceuticals and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olema PharmaceuticalsN/AN/AN/A
Atea PharmaceuticalsN/AN/AN/A

Summary

Olema Pharmaceuticals beats Atea Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Olema Pharmaceuticals (NASDAQ:OLMA) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Olema Pharmaceuticals and Sage Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olema PharmaceuticalsN/AN/AN/AN/AN/A
Sage Therapeutics$6.87 million651.04$-680,240,000.00($13.38)-5.73

Olema Pharmaceuticals has higher earnings, but lower revenue than Sage Therapeutics.

Analyst Recommendations

This is a summary of recent ratings for Olema Pharmaceuticals and Sage Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olema Pharmaceuticals00403.00
Sage Therapeutics08802.50

Olema Pharmaceuticals presently has a consensus price target of $60.6667, indicating a potential upside of 84.73%. Sage Therapeutics has a consensus price target of $87.0625, indicating a potential upside of 13.64%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Sage Therapeutics.

Profitability

This table compares Olema Pharmaceuticals and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olema PharmaceuticalsN/AN/AN/A
Sage Therapeutics-7,706.84%-63.81%-56.64%

Summary

Olema Pharmaceuticals beats Sage Therapeutics on 5 of the 7 factors compared between the two stocks.

Olema Pharmaceuticals (NASDAQ:OLMA) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Olema Pharmaceuticals and Biohaven Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olema PharmaceuticalsN/AN/AN/AN/AN/A
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.36

Analyst Recommendations

This is a summary of recent ratings for Olema Pharmaceuticals and Biohaven Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olema Pharmaceuticals00403.00
Biohaven Pharmaceutical021002.83

Olema Pharmaceuticals presently has a consensus price target of $60.6667, indicating a potential upside of 84.73%. Biohaven Pharmaceutical has a consensus price target of $96.4545, indicating a potential upside of 39.00%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Biohaven Pharmaceutical.

Insider & Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Olema Pharmaceuticals and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olema PharmaceuticalsN/AN/AN/A
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Summary

Olema Pharmaceuticals beats Biohaven Pharmaceutical on 4 of the 7 factors compared between the two stocks.

Olema Pharmaceuticals (NASDAQ:OLMA) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Olema Pharmaceuticals and Hutchison China MediTech's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olema PharmaceuticalsN/AN/AN/AN/AN/A
Hutchison China MediTech$204.89 million20.77$-106,020,000.00($0.80)-36.55

Olema Pharmaceuticals has higher earnings, but lower revenue than Hutchison China MediTech.

Analyst Recommendations

This is a summary of recent ratings for Olema Pharmaceuticals and Hutchison China MediTech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olema Pharmaceuticals00403.00
Hutchison China MediTech00203.00

Olema Pharmaceuticals presently has a consensus price target of $60.6667, indicating a potential upside of 84.73%. Hutchison China MediTech has a consensus price target of $40.00, indicating a potential upside of 36.80%. Given Olema Pharmaceuticals' higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Hutchison China MediTech.

Insider & Institutional Ownership

33.5% of Hutchison China MediTech shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Olema Pharmaceuticals and Hutchison China MediTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olema PharmaceuticalsN/AN/AN/A
Hutchison China MediTechN/AN/AN/A


Olema Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Schrödinger logo
SDGR
Schrödinger
1.5$73.90+4.1%$5.17 billion$85.54 million0.00Insider Selling
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$77.81+0.1%$5.10 billion$1.00 billion-11.79
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51+0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61+0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39+2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24+2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35+1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29+0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95+3.9%$3.87 billionN/A-22.49Analyst Report
News Coverage
Gap Down
LEGN
Legend Biotech
1.2$28.45+6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65+2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77+0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41+0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63+3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60+1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56+0.0%$3.34 billionN/A-5.60News Coverage
Insmed logo
INSM
Insmed
1.2$31.70+2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39+1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42+7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91+0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49+1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02+0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25+0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36+0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84+4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18+2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83+0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68+1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69+0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77+13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44+1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77+1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81+1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41+8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19+0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29+3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47+2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93+1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30+1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75+0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49+16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13+1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09+1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99+2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43+3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35+3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57+0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58+0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02+0.4%$1.88 billionN/A-10.57
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.